Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Rosetta Genomics, Sophia Genetics, and Premaitha Health

NEW YORK (360Dx) – Rosetta Genomics this week announced an agreement to make the RosettaGX Reveal thyroid miRNA classifier and its other testing services accessible through MediNcrease Health Plans’ regional and national health plans, insurance companies, employers, and other parties. MediNcrease is a national provider network and provider advocacy firm.

Sophia Genetics said that six leading healthcare institutions from across Mexico have adopted Sophia artificial intelligence, which provides clinical genomics solutions for cancer and congenital disorders. 

The firm noted that its solutions are tailored to the individual needs of hospitals or laboratories regardless of whether they have NGS testing capabilities or not. Through the company’s software-as-a-service platform, Sophia DDM, clinicians are connected to a network of more than 360 hospitals across 55 countries. Sophia noted that platform enables clinicians and researchers to make sense of genomics data to better and faster diagnose and treat patients.

Premaitha Health said this week that the company has signed several new contracts in the Middle East through its regional distribution network. The firm already has three established customer laboratories in the region. It has secured contracts with three additional laboratories, including in the United Arab Emirates and Saudi Arabia, and it has signed new customers there who will send samples to Premaitha’s service laboratories. 

The firm said it anticipates that the new laboratories will be operational with its Iona test by early 2018. It added that these additional installations will increase the company’s potential addressable market by expanding access into new population groups.

Precipo has completed the consolidation of the Transgenomic CLIA lab, formerly located in Omaha, Nebraska, and moved all CLIA and pharmacological research projects to its CLIA lab in New Haven, Connecticut. Precipio and Transgenomic completed their merger in June. 

The consolidation is expected to trim operating costs by about $500,000. The facility in Omaha will focus exclusively on continued R&D related to the ICE COLD-PCR liquid biopsy technology. Precipio also said that it has signed a deal with an unnamed, existing pharmaceutical client for an additional research project that will generate an expected $750,000 in revenues over the course of the project, which is anticipated to start in the fourth quarter.

UK-based diagnostics supplier Pathway Diagnostics will distribute AroCell’s TK 210 ELISA test in the UK and Ireland under a deal announced this week. The CE-marked immunoassay is for monitoring thymidine kinase 1, an enzyme that is upregulated in tumor cells, according to AroCell’s website. It added that increased serum TK1 protein is associated with tumor growth, and monitoring TK1 is one strategy in individualizing cancer therapy. Financial and other terms of the deal were not disclosed.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.